mRNA therapy for phenylketonuria

Patent metadata

Field	Value
Publication number	US-11377642-B2
Application number	US-201916245828-A
Country	US
Kind code	B2
Filing date	Jan 11, 2019
Priority date	Oct 22, 2013
Publication date	Jul 5, 2022
Grant date	Jul 5, 2022

Abstract

The present invention provides, among other things, methods of treating phenylketonuria (PKU), including administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH) at an effective dose and an administration interval such that at least one symptom or feature of PKU is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.

First claim

We claim:

1. A method of treating phenylketonuria (PKU), comprising systemically administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH), wherein the mRNA comprises a coding nucleotide sequence at least 95% identical to the mRNA sequence of SEQ ID NO: 3, a 5′ untranslated region (UTR) sequence of SEQ ID NO:4, and a 3′ UTR sequence of SEQ ID NO:5 or SEQ ID NO:6, wherein the mRNA is encapsulated within a liposome with a size of less than 100 nm, wherein the liposome comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids, and wherein administration of the composition at an effective dose and at an administration interval results in increased PAH protein level in the liver and in reduced phenylalanine level in the serum as compared to the baseline of PAH and phenylalanine levels before the treatment.

2. The method of claim 1 , wherein the one or more cholesterol-based lipids is cholesterol or PEGylated cholesterol.

3. The method of claim 1 , wherein the cationic lipid constitutes about 30-60% of the liposome by molar ratio.

4. The method of claim 1 , wherein the mRNA is administered at the effective dose ranging from about 0.1-3.0 mg/kg body weight.

5. The method of claim 1 , wherein the composition is administered intravenously.

6. The method of claim 1 , wherein the administering of the composition results in increased serum PAH protein level.

7. The method of claim 1 , wherein the administering of the composition results in reduced phenylalanine level in the serum as compared to the baseline phenylalanine level before the treatment.

8. The method of claim 1 , wherein the mRNA is codon optimized.

9. The method of claim 1 , wherein the mRNA comprises one or more modified nucleotides.

10. The method of claim 1 wherein the mRNA is unmodified.

Assignees

• Translate Bio Inc

Inventors

• Derosa Frank
• Heartlein Michael
• Dias Anusha

Classifications

• A61K38/44

  Oxidoreductases (1) · CPC title

• A61K48/005 Primary

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• C12Y114/16001

  Phenylalanine 4-monooxygenase (1.14.16.1) · CPC title